亚太地区乳腺癌筛查市场预测至 2027 年 - Covid-19 影响和按测试类型（血液标记测试、影像学测试、基因测试、免疫组织化学测试）进行的区域分析、最终用户（医院、诊断中心、癌症研究所、研究实验室）、和国家。
No. of Pages: 155 | Report Code: TIPRE00011577 | Category: Life Sciences
No. of Pages: 155 | Report Code: TIPRE00011577 | Category: Life Sciences
根据美国疾病控制与预防中心 (CDC) 的定义，乳腺癌筛查是指在出现疾病体征或症状之前检查女性乳房是否患有癌症。筛查测试的目的是在早期发现癌症，以便可以进行手术或治愈。有时，筛查测试会发现癌症非常小或生长缓慢。
增加研究活动可能会增强亚太地区的乳腺癌筛查市场。例如，“用于早期乳腺癌检测的血清 microRNA 的新型组合”是在日本进行的。此外，日本政府已启动癌症控制计划，因为它是日本的主要原因之一。在政府的支持下，各城市在全国范围内开展癌症筛查计划。
此外，乳腺癌早期诊断的研究不断增加可能有利于澳大利亚的乳腺癌筛查市场。例如，2019年10月，NBCF资助的（国家乳腺癌基金会）悉尼大学研究人员公布了3D乳房X光检查（称为断层合成）试点试验的结果，根据该研究，3D乳房X光检查的乳腺癌检出率比标准方法更高2D 乳房 X 线摄影。
基于测试类型的市场洞察
根据测试类型，乳腺癌筛查市场分为影像学测试、免疫组织化学测试、基因测试和血液标志物测试。 2019年，影像测试领域占据2019年最大市场份额；此外，预计在预测期内，该市场的复合年增长率将达到最高。
根据终端用户，乳腺癌筛查市场进一步细分为医院、诊断中心、癌症研究所和研究实验室。 2019年，医院细分市场占据最大市场份额；此外，预计在预测期内其复合年增长率将达到市场最高水平。
产品发布和批准是公司在全球范围内扩大业务并满足不断增长的需求时普遍采用的策略。乳腺癌筛查市场的参与者采用扩张、合作和产品发布策略来扩大全球客户群。这些策略使参与者能够在全球范围内保持其品牌知名度。例如，2018年10月，GE医疗在美国推出了一款产品，即Invenia自动乳腺超声（ABUS）2.0。该设备是 FDA 批准的超声辅助乳腺筛查技术，专门用于检测致密乳腺组织中的癌症。
< strong>按测试类型
Strategic insights for Asia Pacific Breast Cancer Screening involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 798.57 Million |
| Market Size by 2027 | US$ 1,120.77 Million |
| Global CAGR (2020 - 2027) | 5.4% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By 检测类型
|
| Regions and Countries Covered | 亚太地区
|
| Market leaders and key company profiles |
The regional scope of Asia Pacific Breast Cancer Screening refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The List of Companies - Asia Pacific Breast Cancer Screening Market
The Asia Pacific Breast Cancer Screening Market is valued at US$ 798.57 Million in 2019, it is projected to reach US$ 1,120.77 Million by 2027.
As per our report Asia Pacific Breast Cancer Screening Market, the market size is valued at US$ 798.57 Million in 2019, projecting it to reach US$ 1,120.77 Million by 2027. This translates to a CAGR of approximately 5.4% during the forecast period.
The Asia Pacific Breast Cancer Screening Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Breast Cancer Screening Market report:
The Asia Pacific Breast Cancer Screening Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Breast Cancer Screening Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Breast Cancer Screening Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Breast Cancer Screening Market
